Evidence map›Paper›PMID 40011942›Full record

ReviewBioelectronic medicine2025

Long COVID - a critical disruption of cholinergic neurotransmission?

Marco Leitzke, Donald Troy Roach, Swen Hesse, Peter Schönknecht, Georg-Alexander Becker, Michael Rullmann, Bernhardt Sattler, Osama Sabri

Abstract readReview
In one paragraph

Review in Bioelectronic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marco LeitzkeDepartment of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, 04103, Germany. marco.leitzke@gmx.de.
Donald Troy RoachSchool of Comillas University, Renegade Research, Madrid, 28015, Spain.
Swen HesseDepartment of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, 04103, Germany.
Peter SchönknechtDepartment of Psychiatry and Neurology Altscherbitz, Schkeuditz, 04435, Germany.
Georg-Alexander BeckerDepartment of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, 04103, Germany.
Michael RullmannDepartment of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, 04103, Germany.
Bernhardt SattlerDepartment of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, 04103, Germany.
Osama SabriDepartment of Nuclear Medicine, University of Leipzig Medical Centre, Leipzig, 04103, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing the COVID-19 pandemic, there are many chronically ill Long COVID (LC) patients with different symptoms of varying degrees of severity. The pathological pathways of LC remain unclear until recently and make identification of path mechanisms and exploration of therapeutic options an urgent challenge. There is an apparent relationship between LC symptoms and impaired cholinergic neurotransmission.

methodsThis paper reviews the current literature on the effects of blocked nicotinic acetylcholine receptors (nAChRs) on the main affected organ and cell systems and contrasts this with the unblocking effects of the alkaloid nicotine. In addition, mechanisms are presented that could explain the previously unexplained phenomenon of post-vaccination syndrome (PVS). The fact that not only SARS-CoV-2 but numerous other viruses can bind to nAChRs is discussed under the assumption that numerous other post-viral diseases and autoimmune diseases (ADs) may also be due to impaired cholinergic transmission. We also present a case report that demonstrates changes in cholinergic transmission, specifically, the availability of α4β2 nAChRs by using (-)-[

resultsA substantial body of research has emerged that offers a compelling explanation for the phenomenon of LC, suggesting that it can be plausibly explained because of impaired nAChR function in the human body. Following a ten-day course of transcutaneous nicotine administration, no enduring neuropathological manifestations were observed in the patient. This observation was accompanied by a significant increase in the number of free ligand binding sites (LBS) of nAChRs, as determined by (-)-[

conclusionsIn conclusion, based on current knowledge, LDTN appears to be a promising and safe procedure to relieve LC symptoms with no expected long-term harm.

Indexed as

Cholinergic neurotransmissionFlubatineLong COVIDLow dose transdermal nicotineNicotinic acetylcholine receptorsSpike glycoprotein

Identifiers

PMID40011942
PMCPMC11866872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.